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BXH-2 mice develop a fatal myeloid leukemia by a two-step mutagenic process. First, a 
BXH-2–specific recessive mutation causes a myeloproliferative syndrome. Second, retroviral 
insertions alter oncogenes or tumor suppressors, resulting in clonal expansion of leukemic 
cells. We have identified a recessive locus on chromosome 8 (
 
Myls)
 
 that is responsible for 
myeloproliferation in BXH-2. This 
 
Myls
 
 interval has been narrowed down to 2 Mb and found 
to contain several positional candidates, including the 
 
interferon consensus sequence–
binding protein 1 
 
gene (
 
Icsbp,
 
 also known as 
 
interferon regulatory factor 8
 
 [
 
IRF8
 
]). We 
show that BXH-2 mice carry a mutation (915 C to T) resulting in an arginine-to-cysteine 
substitution at position 294 within the predicted IRF association domain of the protein. 
Although expression of 
 
Icsbp1 
 
mRNA transcripts is normal in BXH-2 splenocytes, these cells 
are unable to produce interleukin 12 and interferon-
 
 
 
 in response to activating stimuli, 
confirming that R294C behaves as a loss-of-function mutation. Myeloproliferation in BXH-2 
mice is concomitant to increased susceptibility to 
 
Mycobacterium bovis
 
 (BCG) despite the 
presence of resistance alleles at the 
 
Nramp1
 
 locus. These results suggest a two-step model 
for chronic myeloid leukemia in BXH-2, in which inactivation of 
 
Icsbp1 
 
predisposes to 
myeloproliferation and immunodeficiency. This event is required for retroviral replication, 
and subsequent insertional mutagenesis that causes leukemia in BXH-2 mice.
 
Chronic myeloid leukemia (CML) is part of a
group of six myeloproliferative disorders in
humans—that includes polycythemia vera,
chronic idiopathic myelofibrosis, essential throm-
bocythemia, chronic neutrophilic leukemia,
and chronic eosinophilic leukemia—which are
chronic diseases that can progress to acute leu-
kemia (1–3). CML is generally characterized
by the cytogenetically detectable 9:22 translo-
cation known as the Philadelphia (Ph) chro-
mosome, which generates a fusion between
the Abelson tyrosine kinase (p145 
 
ABL
 
) and
the 
 
BCR
 
 gene (breakpoint cluster region;
p160 
 
BCR
 
; reference 4). However, 5–8% of
CML are Ph negative. CML is characterized
by an increased number of mature and imma-
ture granulocytes in the circulating blood, and,
in BM, an increased myeloid/erythroid ratio
and a pronounced splenomegaly (1–3). The
molecular mechanisms underlying proliferation
in Ph-negative CML or in other myeloprolif-
erative disorders remain poorly understood (2).
CML can remain indolent for years, but in-
exorably progresses to an “acceleration” stage
(
 
 
 
5% circulating blasts) and a “blastic” stage
(
 
 
 
30% blasts), which is rapidly fatal (2–6 mo).
Although the mechanisms underlying this evo-
lution are poorly understood, they include in-
activation of tumor suppressor genes 
 
p16
 
 (5)
and 
 
p53
 
 (5) and of the Rb gene product (6)
and include overexpression of EVI-1 (7).
BXH-2 is a recombinant inbred mouse
strain derived from C3H/HeJ and C57BL/6J (8)
that develops a spontaneous myeloid leukemia
uniformly fatal by age one (9–12). The tumors
are clonal and caused by insertional mutagenesis
of a replication competent B-tropic ecotropic
murine leukemia virus (MuLV; references
10–14). In general, mice may carry two types
of ecotropic MuLV, either the B-tropic type
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or the N-tropic type, as defined by the presence of 
 
Fv-1
 
b
 
(N-tropic restricted) or 
 
Fv-1
 
n
 
 (B-tropic restricted)–restrictive
alleles at the 
 
Fv-1
 
 locus on chromosome 4 (13). BXH-2 has
two endogenous replication-defective N-tropic ecotropic
MuLV proviruses that are designated 
 
Emv1
 
 and 
 
Emv2
 
 on
chromosomes 5 and 8, respectively (9). Because BXH-2
mice bear the 
 
Fv-1
 
b
 
 allele, they are not permissive for repli-
cation of N-tropic ecotropic viruses. However, they are per-
missive for replication of B-tropic ecotropic MuLVs and are
known to exhibit maternal passage of a B-tropic ecotropic
virus that is not integrated in the germline of the strain. Re-
combination events can modify tropism of ecotropic viruses,
and a recombination event between 
 
Emv1
 
 and 
 
Emv2
 
 provi-
ruses, and/or xenotropic virus, is thought to generate the
replication-competent B-tropic ecotropic MuLV that causes
leukemia in BXH-2 (10–12). BXH-2 leukemia are of mye-
loid origin, with cells not differentiating beyond the myelo-
blastic stage being negative for azurophilic granules and
myeloperoxidase (10). Interestingly, although other BXH
strains (BXH-3, -9, and -12) carry both 
 
Emv1
 
 and 
 
Emv2
 
,
only BXH-2 develops adult onset leukemia (9). In addition,
the replication-competent B-tropic ecotropic virus of BXH-2
can induce myeloid leukemia and B cell lymphoma when in-
oculated into newborns from other permissive BXH strains
(10, 11). This suggests that additional BXH-2–specific genetic
effects underlie leukemia establishment in these mice.
During the course of an investigation of the unique sus-
ceptibility to 
 
Mycobacterium bovis
 
 (BCG) infection of BXH-2
(15), we noted that BXH-2 mice show splenomegaly (spleen
index 
 
  
 
0.9), which is a phenotype not observed in C57BL/
6J and C3H/HeJ progenitors (spleen index 
 
  
 
0.5–0.8). In
F1 and F2 crosses between BXH-2 and -3 and other inbred
strains (C57BL/6J, BALB/cJ, and A/J), splenomegaly be-
haved as recessive and segregated as a monogenic trait that
was given the temporary designation 
 
Myls
 
 (16). Histological
analyses showed that homozygosity at 
 
Myls
 
 results in abnor-
malities in the spleen, LNs, and BM, and, most important,
results in the infiltration of Mac1
 
 
 
/Gr1
 
 
 
 granulocyte pre-
cursors and the presence of pseudo-Gaucher cells. At 8–16
wk old, hematological parameters of 
 
Myls 
 
(
 
 
 
/
 
 
 
) homozy-
gotes were normal. Expansion of the Mac1
 
 
 
/Gr1
 
 
 
 compart-
ment appeared restricted to the spleen, LNs, and BM at that
young age. These results suggested that BXH-2 mice suffer
from a myeloproliferative syndrome caused by a mutation
(
 
Myls
 
) that occurred during the breeding of this strain. A
whole genome scan conducted in 187 informative [BALB/
cJ 
 
 
 
 BXH-2]F2 mice localized 
 
Myls
 
 to an 18-cM interval in
the distal portion of chromosome 8 near marker 
 
D8Mit13
 
(LOD 
 
 
 
 44; map position 125 Mb; reference 16). Although
the 
 
Myls
 
 interval contains many genes, it harbors 
 
Emv2
 
, one
of the two endogenous N-tropic ecotropic MuLV integrated
in BXH-2. Because BXH-2 develops B-tropic ecotropic
MuLV-induced myeloid leukemia at high frequency, a pos-
sible relationship between 
 
Emv2
 
 and 
 
Myls
 
 was investigated.
However, 
 
Myls
 
 and 
 
Emv2
 
 appear to be distinct loci because
(a) 
 
Myls
 
 is inherited as a recessive trait as opposed to a trait
caused by a replication-competent virus, which would be
inherited in a dominant fashion; and (b) only a fraction of
[A/J 
 
 
 
 BXH-2]F2 mice homozygous for 
 
Myls
 
 and showing
splenomegaly demonstrate B-tropic ecotropic MuLV viral
titer in their spleen (16). These results have suggested that
BXH-2 carry a recessive loss-of-function mutation at 
 
Myls
 
that causes initial proliferation of 
 
Mac1
 
 
 
/
 
Gr1
 
 
 
 granulocyte
precursors. This proliferation is most likely necessary or pro-
vides favorable conditions for a second insertional mutagen-
esis event that is caused by a replication-competent B-tropic
ecotropic MuLV virus, thus resulting in clonal myeloid leu-
kemia typical of BXH-2. The aim of the present study was
to use positional cloning to identify the gene and protein
underlying the 
 
Myls
 
 effect.
 
RESULTS
CML-like syndrome in BXH-2 mice
 
The recombinant inbred mouse strain BXH-2 develops sple-
nomegaly as early as 6 wk old, which is not only characterized
by an abundant infiltration of the spleen, but also infiltration
of the LNs and the BM, with 
 
Mac1
 
 
 
/
 
Gr1
 
 
 
 myeloid precur-
sors of the granulocytic lineage showing typical ring-shaped
nuclei (Fig. 1 A). This phenotype is controlled by a single,
BXH-2–specific locus, 
 
Myls
 
, which is inherited in a recessive
manner (Fig. 1 C) and maps on chromosome 8 (16). BXH-2
mice and [A/J 
 
 
 
 BXH-2]F2 mice homozygotes for 
 
Myls
 
(
 
 
 
/
 
 
 
) go on to die within 10 mo of age (Fig. 1 B), most
probably due to fatal leukemia, compared with control A/J
and [A/J 
 
 
 
 BXH-2]F2 heterozygotes (
 
 
 
/
 
 
 
) or homozy-
gotes (
 
 
 
/
 
 
 
) for wild-type alleles at 
 
Myls
 
 locus (defined by
 
D8Mit200
 
 and 
 
D8Mit14
 
) that show 90% survival after 12 mo.
This fatal leukemia in 
 
Myls
 
 homozygotes probably involves
insertional mutagenesis by a replication-competent B-tropic
ecotropic MuLV (10–14). Results in Fig. 1 C show that the
splenomegaly phenotype occurs in [C3H 
 
 
 
 BXH-2]F2 of
either 
 
Fv-1
 
b/b
 
 (3/16), 
 
Fv-1
 
b/n
 
 (10/16), or 
 
Fv-1
 
n/n
 
 (3/16) ge-
notypes, the latter of which are not permissive for B-tropic
ecotropic MuLV replication (17). Considering that the
B-tropic ecotropic MuLV cannot replicate in mice bearing
the 
 
Fv-1
 
n
 
 allele, we assume that the splenomegaly pheno-
type is independent of B-tropic ecotropic MuLV infection
and replication.
 
High resolution linkage map of 
 
Myls
 
The minimal genetic interval for 
 
Myls
 
 was initially defined as
9 Mb in size (16), as delineated by 
 
D8Mit200
 
 (map position,
116 Mb) on the proximal side and by 
 
D8Mit13
 
 (map posi-
tion, 125 Mb) on the distal side (Fig. 2 A). This region con-
tains several candidate genes including 
 
Emv2
 
, an N-tropic
ecotropic MuLV, and the protooncogene 
 
c-maf
 
 in which al-
terations are associated with certain forms of leukemia (18, 19).
Thus, we reduced the minimal genetic interval of the 
 
Myls
 
locus using additional single nucleotide polymorphism
(SNP) markers from the region (
 
rs3681178
 
, 
 
mCV23936616
 
, 
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mCV22708293, and mCV25191372) informative between
A/J and BXH-2. The allelic combination at these markers
was established by nucleotide sequencing in a subgroup of
37 [A/J   BXH-2]F2 mice that shows recombinations be-
tween D8Mit200 and D8Mit14 and that had been pheno-
typed for splenomegaly. Our study of these recombinants
further reduced the Myls interval to  2 Mb, as delineated by
mCV23936616 on the proximal side (seven crossovers) and
by rs3681178 on the distal side (eight crossovers; Figs. 2 B
and 4 D). This analysis excluded c-maf and Emv2 as candi-
dates for Myls. Searches of public databases identified a mini-
mum of 14 annotated transcripts in this interval including
proteins involved in interaction with different forms of actin
(Cotl1), cysteine protease (Uchrp), cytochrome c oxidase
(Cox4a), interferon-mediated immunity (Icsbp1/IRF-8), de-
velopmental processes (Foxf1a), formation of mesenchymal
tissues (Foxc2), regulation of Wnt receptor signaling pathway
and proteoglycan biosynthesis (Foxl1), nonmotor microtu-
bule binding (Map1lc3), glycerophospholipid metabolism
(Jph3), amino acid transport (Slc7a5), carbonate dehydratase
and lyase (Car5a), as well as unknown functions (Zdhhc7,
Noc4, Bdg29; Fig. 2 C).
Myls is caused by a mutation in Icsbp/IRF-8 specific to BXH-2
Analysis of candidate genes from the Myls interval with re-
spect to the available functional data, and tissue- and cell-
specific expression, identified Icsbp/IRF-8 (interferon consensus
sequence–binding protein/interferon regulatory factor 8) as a very
strong positional candidate. Icsbp/IRF-8 is a transcription fac-
tor member of the IRF family that is expressed in lymphoid
organs and is known to play a role in myeloid cell lineage se-
lection (20). IRF-8 also plays a critical role in mediating tran-
scriptional activation of a group of IFN- –responsive genes
by binding to specific sequence motifs and recruitment of
other transcription factors (21). In splenocytes, IRF-8 is itself
induced by exposure to IFN-  and LPS (20). The expression
of IRF-8 transcripts was analyzed by Northern blotting in
spleens from BXH-2, A/J, and from [A/J   BXH-2]F2 mice
showing (Fig. 3 A; high SI, Myls  / ) or not splenomegaly
(Fig. 3 A; low SI, Myls  / ). As previously reported (22),
Figure 1. Phenotypic characteristics of the Myls mutation in BXH-2 
mice and in F2 mice derived from BXH-2. (A) The Myls mutation 
causes splenomegaly and myeloproliferation. Spleen sections (red pulp) 
from [BALB/cJ   BXH-2]F2 mice homozygotes for the Myls mutation were 
stained with hematoxylin and eosin and photographed at 40 and 100X 
magnification. Myeloproliferation in Myls mutants involves infiltration of 
Mac1 /Gr1  neutrophil precursors with their characteristic ringlike nuclei. 
(B) Longevity of A/J, BXH-2, and [A/J   BXH-2]F2 mice according to their 
Myls haplotypes ( / , homozygote for Myls;  / , heterozygote; and  / , 
homozygote wild type, respectively). Myeloproliferation in Myls homozygotes 
results in uniform death of these mice by 10 mo of age. (C) Phenotypic 
expression of myeloproliferation/splenomegaly in Myls homozygotes occurs 
before, and is independent of, B-tropic ecotropic MuLV virus replication. 
BXH-2 ( / ), C3H/HeJ ( / ), and [BXH-2   C3H]F1 controls ( / ), as 
well as segregating [C3H   BXH-2]F2 mice (8–16 wk old) were pheno-
typed for splenomegaly, demonstrating the effect of homozygosity at Myls. 
Further classification of Myls ( / ) homozygotes according to their 
genotype for the Fv-1 locus that controls replication of ecotropic MuLVs 
shows that splenomegaly occurs in F2 mice permissive (Fv1b/b) or not (Fv1b/n, 
Fv1n/n) to B-tropic ecotropic MuLV replication.IRF-8 IN IMMUNODEFICIENCY AND CML IN BXH-2 | Turcotte et al. 884
the  IRF-8 gene produces two transcripts in the spleen of
 3.0 and 1.7 Kb, respectively. Neither the size nor the rela-
tive abundance of the IRF-8 transcripts in spleen appeared to
be affected by the Myls mutation when compared with the
 -actin that was used as control (Fig. 3 A). Similar results
were obtained by semi-quantitative and quantitative analysis
using RT-PCR (Fig. 3 B and not depicted). Likewise, IRF-8
mRNA transcripts could be induced in splenocytes after LPS/
IFN-  stimulation (Fig. 3 B), and this induction was similar
in normal (C57BL/6J) and in Myls mutant mice (BXH-2).
Members of the IRF family share a highly conserved,
COOH-terminal, DNA-binding domain (DBD) that con-
tains a characteristic conserved tryptophan repeat and binds
to similar DNA sequences, termed IRF element, inter-
feron-stimulated response element, interferon consensus se-
quence, or Ets-IRF composite elements present in the pro-
moter of target genes (23). The COOH-terminal portion
of the protein contains a trans-activation domain, the IRF
association domain (IAD), which is poorly conserved and is
implicated in recruiting other transcription factors includ-
ing members of the IRF family to assemble a transcriptional
complex (23). Nucleotide sequencing of the IRF-8 tran-
script (Fig. 4 A) from BXH-2 identified a C-to-T substitution
at position 915 of the cDNA, causing an arginine-to-cysteine
replacement at amino acid position 294 (R294C) within
the predicted IAD domain of the protein (Fig. 4 B). This
polymorphism appears specific for BXH-2 and is absent in
the C57BL/6J parent, from which the Myls-IRF-8 portion
of chromosome 8 in BXH-2 is derived (Fig. 4 A). The
R294C substitution in IRF-8 modifies a HaeIII restriction
site in genomic DNA that provides a convenient genomic
marker for the mutation (Fig. 4 C). A total of 12 standard
inbred mouse strains (including C57BL/6J and C3H/HeJ
parents; unpublished data), together with the 11 available
BXH strains were genotyped for the HaeIII polymorphism
(Fig. 4 C). None of the strains tested displayed the R294C-
specific variant, verifying that IRF-8C294 is unique to BXH-2.
Additional segregation analysis in the 37 [A/J   BXH-2]F2
mice exhibiting recombination between D8Mit200 and
D8Mit14 in the Myls interval showed complete concor-
dance between IRF-8 alleles (determined by the HaeIII
polymorphism) and the presence or absence of spleno-
megaly (Fig. 4 D, hatched boxes [high SI] and empty boxes
[low SI]). Finally, R294 is conserved in the chicken and
human IRF-8 protein homologues, and R294C is a non-
conservative substitution removing a positive charge at the
Figure 2. High resolution linkage and physical map of the Myls region. 
(A) Genetic interval for Myls was delimited by proximal marker D8Mit200 
and distal marker D8Mit13, corresponding to a 9-Mb interval on chromo-
some 8. The centromere is identified by a large dot. Marker positions 
(measured in megabases) are based on the Celera Discovery System Online 
Platform. (B) Fine mapping of Myls interval using SNP markers in 37 infor-
mative [A/J   BXH-2]F2 mice excluded candidate genes c-maf and Emv2 
and reduced the Myls candidate interval to 2 Mb with border markers 
mCV23936616 and rs3681178. Intermarker distances (measured in mega-
bases), based on CDS Online Platform, are shown within each interval (C) 
The reduced Myls interval contains a minimum of 14 known genes present 
in the NCBI databases and includes the candidate gene Icsbp/IRF-8.
Figure 3. Expression of IRF-8 RNA in the spleens of A/J, B6, BXH-2, 
and BXH-2–derived F2 mice. (A) Total RNA was extracted from the spleens 
of BXH-2 ( / ), A/J ( / ), and [A/J   BXH-2]F2 animals displaying 
(high SI;  / ) or not displaying (low SI;  / ) splenomegaly, was analyzed 
by Northern blotting with a cDNA fragment corresponding to part of the 
DBD (from  179 to  326) of IRF-8, and used as a hybridization probe. 
(B) RT-PCR analysis of IRF-8 mRNA expression in splenocytes from C57BL/6J 
and BXH-2 either before (naive) or after treatment with LPS and IFN- . 
 -Actin mRNA expression was used as an internal control. Products from 
RT-PCR reactions performed in the absence of reverse transcriptase ( RT) 
or in the absence of RNA template (H2O) were included as negative controls, 
and all PCR products were analyzed by agarose gel electrophoresis.JEM VOL. 201, March 21, 2005 885
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294 position and introducing a smaller residue with a po-
tential for disulfide bonding. Although R294 is not con-
served in other members of the mouse IRF protein family,
a basic residue is usually found at this position with the ex-
ception of ISGF3  that harbors a proline (24). An induced
mutation at position 289 (R289E) in IRF-8, within an  
helix of the IAD domain, was previously shown to disrupt
the interaction of IRF-8 with PU.1 (25), demonstrating the
importance of this region for transactivation. Together,
these results establish that IRF-8C294 is a new mutation that
appeared on the B6 background of BXH-2 and became
fixed during the inbreeding of this strain. This mutation is
either tightly linked or identical to Myls.
IRF-8C294 impairs cytokine production by BXH-2 splenocytes
We next investigated the effect of the R294C substitution
on IRF-8 protein activity. IRF-8 is known to be essential
for transcriptional activation of the IL-12p40 subunit gene,
and for the production of IL-12 and IFN-  by splenocytes
in response to LPS stimulation (26). Thus, splenocytes
from BXH-2 (IRF-8C294) and from C57BL/6J and A/J
controls (IRF-8R294) were harvested and stimulated with ei-
ther LPS (100 ng/ml) or with LPS (100 ng/ml)   IFN- 
(200 U/ml). Production of IL-12 (LPS   IFN-  treat-
ment; Fig. 5 A) and IFN-  (LPS treatment; Fig. 5 B) was
monitored in culture supernatants by ELISA, and RNA
was extracted from the stimulated cells for analysis of IL-
12p40 and IL-12p35 mRNA production by RT-PCR
(Fig. 5 C). Although stimulation caused IL-12 and IFN- 
production by control A/J and B6 splenocytes, BXH-2
spleen cells did not secrete detectable amounts of IL-12 and
IFN-  in response to the same treatments. Failure of
BXH-2 splenocytes to secrete IL-12 was associated with
reduced transcriptional activation of the IL-12p40 gene
when compared with B6, and as estimated by semi-quanti-
tative RT-PCR (Fig. 5 C) and quantitative RT-PCR (not
depicted). Together, these results demonstrate that the
IRF-8C294 protein isoform is functionally impaired in BXH-2,
and can no longer mediate transcriptional activation of
IFN-  responsive genes.
Figure 4. The IRF-8 gene is mutated in BXH-2 mice. (A) Coding exons 
of IRF-8 gene were completely sequenced in C57BL/6J and BXH-2 mice. 
A C-to-T mutation at cDNA position 915 within exon 7 was found in BXH-2 
mice. (B) Genomic organization of the IRF-8 gene, including the position 
of individual noncoding (open boxes) and coding (closed boxes) exons 
(E1–E9). The position of individual coding exons with respect to known 
structural features of the IRF-8 protein, including the DNA-binding domain 
(DBD) and the IRF association domain (IAD), is shown. The C915T nucleotide 
substitution results in an Arg-to-Cys change at amino acid position 294 of 
the protein (R294C) in the IAD, which is shown as an alignment of the B6 
and BXH-2 sequences in this region. (C) C915T disrupts a HaeIII restriction 
site (ggcc) in genomic DNA that can be assayed by PCR amplification, 
digested by HaeIII, and analyzed by agarose gel electrophoresis. Analysis 
of the BXH strains set (numbered 2–19) indicates that C915T mutation is 
specific for BXH-2. (D) Haplotype map of the 37 [A/J   BXH-2]F2 mice 
showing single recombination events between D8Mit200 and D8Mit14 
that were used to define the Myls interval. Each column represents a 
chromosomal haplotype and the total number of animals bearing this 
haplotype is indicated at the bottom (n). For genetic markers D8Mit200, 
mCV23936616, IRF-8, rs3681178, and D8Mit14, homozygosity for BXH-2 
(closed boxes, C57BL/6J derived) or heterozygosity (half-shaded boxes) is 
identified. The presence (hatched boxes, high SI) or absence (open boxes, 
low SI) of splenomegaly is shown.
Figure 5. Effect of IRF-8C294 mutation on IL-12 and IFN-  production. 
Spleen cells from A/J, C57BL/6J (B6), and BXH-2 mice were harvested and 
cultured in the presence of either LPS only (100 ng/ml; B), or LPS (100 ng/
ml) and IFN-  (200 U/ml; A and C) for 24 h, and the levels of IL-12 and 
IFN-  were determined in the culture supernatant by ELISA. In parallel, 
RNA was extracted from cultured splenocytes and used as a template to 
monitor the levels of expression of IL-12p40, IL-12p35, and  -actin tran-
scripts by RT-PCR. RT-PCR reaction products were analyzed by gel electro-
phoresis as described in the legend for Fig. 3. The error bars in A and B 
represent the SEM. IRF-8 IN IMMUNODEFICIENCY AND CML IN BXH-2 | Turcotte et al. 886
IRF-8C294 increases susceptibility to intracellular infection in 
BXH-2
Nramp1 functions as a pH-dependent metal (e.g., Fe2 ,
Mn2 , and Zn2 ) efflux system at the phagosomal membrane
of macrophages to prevent intracellular replication of differ-
ent pathogens (27). Nramp1 mutations abrogate resistance to
infection with Mycobacterium, Salmonella, and Leishmania spe-
cies in mice (28). Inbred mouse strains harbor either a sus-
ceptibility (Nramp1D169; C57BL/6J, BALB/cJ) or a resistance
(Nramp1G169; C3H/HeJ, A/J, DBA/2) allele at Nramp1, with
susceptibility being fully recessive (29). Although BXH-2
mice bear a C3H-derived resistance Nramp1 allele (G169),
they show increased susceptibility to infection with M. bovis
(BCG) (reference 15). The susceptibility phenotype of
BXH-2 is variable, with spleen CFU counts at the peak of
infection being between 5- (Fig. 6) and 100-fold (15) supe-
rior to those seen in parental C3H controls. This variability
appears to be related, in part, to the age at which BXH-2
mice are tested, and possibly linked to the appearance of leu-
kemia. To monitor the possible effects of loss of function at
IRF-8 on resistance to M. bovis (BCG) infection, a number
of F2 crosses were derived between BXH-2 (IRF-8C294,
Nramp1G169) and other inbred strains fixed for either suscep-
tibility (D169; C57BL/6J, BALB/cJ) or resistance (G169;
A/J, C3H/HeJ) alleles at Nramp1. Spleen CFU counts 3 wk
after i.v. infection with 2   104 live M. bovis (BCG) were de-
termined, and the effect of wild-type (R294) or mutant
(C294) alleles at IRF-8 on Nramp1-determined resistance
(G/G and G/D) or susceptibility (D/D) to infection was
evaluated (Fig. 6). Homozygosity for the mutant IRF-8C294
allele was found to be associated with increased mycobacte-
rial replication in most F2 animals (Fig. 6), irrespective of
their parental origins or Nramp1 genotype. The effect was
most obvious in resistant animals either homozygous (G/G)
or heterozygous (G/D) for Nramp1 resistance alleles, and
caused a five- to eightfold increase in spleen CFUs, depend-
ing on the cross that was analyzed. The mutant IRF-8C294 al-
lele effect on bacterial replication was completely recessive,
which was in agreement with the loss of activity seen for
C294 in functional assays (Fig. 5). These results indicate that
loss of IRF-8 function in BXH-2 not only predisposes mice
to leukemia, but also increases susceptibility to infection
with an intracellular pathogen.
DISCUSSION
We have used a positional cloning approach to identify the
mutation that underlies the myeloproliferative disorder char-
acteristic of BXH-2. High resolution linkage mapping in a
large number of informative mice succeeded in excluding
two positional candidates, Emv2 and c-maf. Emv2 corresponds
to an integrated copy of a replication-defective N-tropic
ecotropic MuLV virus (30, 31), and the acute leukemia of
BXH-2 is known to be caused by a replication-competent
B-tropic recombinant ecotropic MuLV virus (9, 10, 12).
The protooncogene c-maf is deregulated in certain tumors,
including multiple myeloma (32). Instead, our studies sug-
gest that IRF-8 is the gene affected in BXH-2 because of the
following: (a) IRF-8 maps within the minimal 2-Mb genetic
interval of Myls; (b) IRF-8 is known to play a critical role in
monocyte maturation, and IRF-8-deficient mice show a
proliferation of granulocytes (26) and are immunocompro-
mised (33, 34); (c) myeloproliferation in BXH-2 is associated
with a sequence variant (R294C) in IRF-8 that is unique to
BXH-2, and is neither found in other BXH strains nor
found in other inbred strains, which affects a charge that is
conserved in other members of the IRF family; and (d) as
opposed to controls, spleen cells expressing the IRF-8C294
variant cannot produce IFN-  and IL-12 in response to LPS.
Figure 6. Effect of IRF-8C294 mutation on Nramp1-dependent 
replication of M. bovis (BCG) in the spleen of segregating BXH-2–
derived F2 mice. Parental strains BXH-2 (IRF-8C294, Nramp1G169) and BCG-
susceptible C57BL/6J and BALB/cJ (IRF-8R294, Nramp1D169), or BCG-resistant 
C3H/HeJ and A/J control strains (IRF-8R294, Nramp1G169) were infected with 
M. bovis (BCG), and spleen CFU counts were determined 3 wk later. F1 and 
F2 crosses were derived from BXH-2 and either C57BL/6J (B6), BALB/cJ (BALB), 
C3H/HeJ (C3H), or A/J, in the combinations indicated at the top of each graph. 
F2 mice were genotyped for Nramp1 (G, resistant; D, susceptible) and for 
IRF-8 alleles (C, mutant; R, wild type) and separated according to their 
haplotype combinations. The allelic status for Nramp1 and for IRF-8 is 
indicated at the top and bottom of the graphs, respectively. Dots represent 
individual mice, and means for each group are shown as lines on the graph. 
Asterisks indicate that the effect of homozygosity for IRF-8C294 is statisti-
cally significant in that Nramp1 haplotype group (P   0.05, unpaired 
Student’s t test).JEM VOL. 201, March 21, 2005 887
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These findings elucidate the molecular basis of the unique
CML-like disease of BXH-2 mice, and they establish BXH-2
as a valuable mouse model to study the two-step process un-
derlying onset and progression of CML and other myelopro-
liferative disorders. In humans, CML is typified by an initial
chronic period with predominant granulocytic involvement,
and this is followed by an advancement and rapidly fatal blast
crisis that is characterized by clonal expansion of leukemic
cells. In BXH-2, the initial chronic phase is caused by the
R294C loss-of-function mutation in IRF-8 that occurred
during the breeding of this strain. These results suggest a tu-
mor suppressor status of IRF-8 in myeloid leukemia (35),
and agree with recent results showing that IRF-8 can antago-
nize the pro-neoplastic effect of ABL-BCR fusions (36–38).
Although loss of function at IRF-8 is necessary for leukemia
in BXH-2, it does not appear to be sufficient. 
A second mutagenic event is provided by insertional mu-
tagenesis with a replication-competent B-tropic ecotropic
MuLV virus, which results in inactivation of additional tu-
mor suppressors and/or activation of protooncogenes, lead-
ing to rapid expansion of clonal tumors in these mice (14,
39). This two-step model explains why (a) other BXH
strains that carry Emv1 and Emv2 copies but are wild type for
IRF-8 do not develop leukemia, and (b) that the replication-
competent B-tropic ecotropic virus of BXH-2 can induce
myeloid leukemias and B cell lymphomas when inoculated
into newborns of other mouse strains (10, 11). Thus, the
myeloproliferative syndrome associated with inactivation of
IRF-8 appears to be necessary for the production of a repli-
cation-competent B-tropic ecotropic virus. Indeed, we have
previously reported that although  50% of [A/J   BXH-
2]F2 mice homozygote at Myls ( / ) have detectable virus
in their spleen, none of [A/J   BXH-2]F2 mice either het-
erozygote (Myls/ ) or homozygote ( / ) wild type show
B-tropic ecotropic MuLV in their spleen when tested by XC
plaque assay (16). This facilitation could be achieved through
enhanced replication of Emv1/Emv2, such as that recently
documented for the hepatitis C virus replicons in Huh7 cells
where IRF-1 expression was reduced (40), or through an in-
creased probability of recombination event between RNA
transcripts produced by the replication-defective Emv1 (mu-
tated in env) and Emv2 (mutated in pol) proviruses provided
by the cellular background of actively replicating Mac1 /
Gr1  cells, or both. Although other genetic and environ-
mental factors may also favor progression of IRF-8C294 cells
to malignant transformation, the virally dependent inser-
tional mutagenesis event of BXH-2 appears to be both more
efficient and more rapid path to acute leukemia. Indeed,
[129    C57BL/6J] mice lacking endogenous replication-
competent retrovirus but carrying a null mutation at IRF-8,
show a very similar pathology (hepato-splenomegaly, myelo-
proliferation of Mac1 /GR1  cells, presence of pseudo-
Gaucher cells), but significantly reduced mortality (33%
mortality by 50 wk; reference 26) when compared with
BXH-2 (100% mortality by 40 wk). In addition, these aging
[129   C57BL/6J] mice also develop histiocytic sarcomas
(41), which are indicative of strain background effects on
disease. Together, these results highlight the possible impor-
tance of IRF-8 in the etiology of human leukemia.
BXH-2 mice show increased susceptibility to infection
with M. bovis (BCG) (15), despite the presence of a resis-
tance allele at Nramp1(G169). This phenotype is variable (15
and unpublished data), age dependent, and may be second-
ary to the onset of acute leukemia in these mice, as opposed
to a direct effect of IRF-8 mutation. The effect of IRF-8
mutation on the susceptibility to M. bovis (BCG) was studied
in animals derived from four different F2 crosses between
BXH-2 and other inbred mouse strains of resistant or sus-
ceptible Nramp1 genetic background. As opposed to infec-
tion with intracellular pathogens Toxoplasma gondii (33) and
Leishmania major (34), where loss of function at IRF-8 causes
acute susceptibility, the IRF-8C294 allele did not abrogate the
major protective effect of Nramp1 at peak of infection (3 wk
after infection). Instead, homozygosity for IRF-8C294 caused
a moderate increase in CFU counts in the spleen at the peak
of infection, and this was true for all three Nramp1 genotypes
studied. Thus, IRF-8 appears to act as a true modulator of
Nramp1 expression or function. The effect could be indirect,
through reduced production of IL-12 and IFN- , two cy-
tokines that play a critical role in host defenses against myco-
bacterial infections, or could be direct through transcrip-
tional regulation of the Nramp1 gene, the promoter of which
contains interferon response elements. Although additional
experiments will be required to distinguish the two possibili-
ties, these results raise the possibility that naturally occurring
polymorphic variants in human IRF-8 may act as predispos-
ing factors for susceptibility to mycobacterial infections (lep-
rosy and tuberculosis) in areas of endemic disease.
IRF-8 is a member of the IRF family whose common
structural features include a DBD and an IAD (23). The
DBD only binds DNA by interacting with other transcrip-
tion factors, including other members of the IRF family
(21). Deletion studies have shown that the IAD mediates
interaction with other proteins. Both an   helix with am-
phipathic character at position Ser325-Phe334 and phosphory-
lation of a serine at position 260 (Ser260) are known to be
essential for interaction of IRF-8 with other IRFs (21). The
R294C mutation of BXH-2 maps in the IAD region and
affects a residue whose positive charge has been conserved in
other IRF proteins. In addition, R294C maps within a well-
conserved portion of the otherwise divergent IAD, which is
immediately downstream the Arg-Leu-Cys motif that is pre-
cisely conserved in IRF-4, -5, -6, -8, and -9 (21). The
R-to-C replacement is not conservative and results in the loss
of a positive charge, which may play an important structural
or functional role. In addition, it introduces a sulfhydryl side
chain at that position with the potential to form a highly dis-
ruptive disulfide bond with other neighboring cysteine resi-
dues. Thus, this mutation may affect interaction with other
IRF proteins and may prevent formation of a transcription-IRF-8 IN IMMUNODEFICIENCY AND CML IN BXH-2 | Turcotte et al. 888
ally active DNA binding complex. Although speculative,
this proposal is in agreement with the noted inability of
IRF-8C294 to mediate induction of target genes such as IL-
12p40 in response to LPS and IFN-  stimulation. Finally,
IRF-8C294 maps near R289E, a mutation within the   helix
of the IAD domain that was recently shown to disrupt the
interaction of IRF-8 with PU.1 (25), demonstrating the im-
portance of this region for transactivation. Additional exper-
iments are currently being conducted to determine the mo-
lecular basis for the loss of function in IRF-8C294.
MATERIALS AND METHODS
Animals. Inbred C57BL/6J, BALB/cJ, C3H/HeJ, and A/J mice were
purchased from the Jackson Laboratory. Recombinant inbred BXH-2 male
mice were originally obtained from the Jackson Laboratory (as single male
animals in the mid-1990’s) and were used to generate F2 crosses with
BALB/cJ, C57BL/6J, and A/J mice that were phenotyped for the presence
of splenomegaly and their susceptibility to M. bovis (BCG) infection. An in-
dependent BXH-2 stock (a gift from N. Copeland and N. Jenkin, National
Cancer Institute, Frederick, MD) was obtained in the early 2000’s and was
subsequently maintained as a breeding colony at McGill University. This
latter stock was used to produce additional F2 crosses that were used for
high resolution linkage mapping of Myls. F2 progeny were produced by
systematic brother–sister mating, with no gender bias. Maintenance and ex-
perimental manipulation of animals were performed according to the guide-
lines and regulations of the Canadian Council on Animal Care.
Histology. Spleens were harvested from [A/J   BXH-2]F2 mice at least 3
mo old. Tissues were fixed in Bouin’s solution (9 g/liter picric acid, 4% acetic
acid, 4% formaldehyde, and 4% methanol), embedded in paraffin, and sec-
tioned as we have described previously (16). 5- m sections were stained with
hematoxylin and eosin and photographed at 40 and 100  magnification.
Genotyping. Genomic DNA was prepared from tail biopsies by incubat-
ing in lysis buffer (100 mM Tris-HCl, pH 8.0, 5 mM EDTA, pH 8.0, 200
mM NaCl, and 0.2% SDS) containing 0.5 mg/ml proteinase K (at 55 C for
16 h) followed by phenol/chloroform extraction and precipitation with
isopropanol (42). Primer pairs defining dinucleotide repeat markers—
D8Mit200, D8Mit14, and D8Mit13 (Myls locus)—were obtained from In-
vitrogen, or in the case of D1Mcg2 and D1Mcg4 (Nramp1), were synthesized
in-house. Marker positions in this study were those from the Mouse Ge-
nome Assembly, presented at the University of California Santa Cruz Bio-
informatics website or the Celera Discovery System Online Platform. Se-
quence length polymorphisms were genotyped by a standard PCR-based
method using  -[32P]dATP labeling and separation on denaturing 9% poly-
acrylamide gels (42). SNPs from the Myls region and informative for A/J
and C57BL/6J (BXH-2) were obtained from the Celera Discovery System
and Celera’s associated databases (mCV25191372,  mCV22708293, and
mCV23936616) and from the National Center for Biotechnology Informa-
tion (NCBI) dbSNP database (rs3681178). Primer pairs defining each SNP
were designed and used for PCR amplification using genomic DNA as a
template. The PCR products were subjected to cycle sequencing using flu-
orescently labeled BigDye Terminator and an automated ABI3700 instru-
ment (Applied Biosystems).
Sequencing of IRF-8 and alleles identification. The transcript map of
the chromosome 8 region overlapping Myls was obtained from the Mouse
Genome Assembly using the University of California Santa Cruz Bioinfor-
matics web browser. Individual coding exons of IRF-8 were obtained by
standard PCR amplification using primer pairs derived from intronic se-
quences, and genomic DNA from C57BL/6J and BXH-2 as templates. PCR
products were subjected to cycle sequencing using fluorescently labeled Big-
Dye Terminator, and an automated ABI3700 instrument. Sequences were
validated by standard dideoxynucleotide sequencing using  -[33P]dATPs
(43). A single nucleotide polymorphism (C915T; Arg294Cys) was identified
in exon 7 of the IRF-8 gene of BXH-2. This sequence variant abolishes a
HaeIII cleavage site (5 -ggcc-3 ) in BXH-2, which can be scored by HaeIII
digestion of a 397-bp exon 7 fragment generated by PCR amplification of
genomic DNA with the oligonucleotide primer pair 5 -gct ccc cat ctt cta
ggc-3  and 5 -acc acc tcg tcc cgc tc-3 , followed by separation on 2% agarose
gel and visualization of ethidium bromide–stained products under UV.
Cytokine production. Mice were killed under anesthesia and spleens
were removed aseptically. Spleen cell suspensions were obtained by gently
disrupting the tissue by passing though a 70- m mesh in 3 ml RPMI 1640
medium supplemented with 10% heat-inactivated FBS, 2 mM glutamine,
100 U/ml penicillin, 50  g/ml streptomycin (GIBCO BRL), 10 mM
Hepes, pH. 7.6, and 5 mM  2-mercaptoethanol. Splenocytes were ob-
tained after incubation of spleen cells with hemolytic Gey’s solution as de-
scribed previously (44). They were seeded in tissue culture vessels at 5  
106 cells/ml followed by incubating with phenol-extracted LPS from Esche-
richia coli O55:B5 (100 ng/ml; Sigma-Aldrich) and murine recombinant
IFN-  (200 U/ml; Sigma-Aldrich) for 24 h at 37 C. Tissue culture super-
natants from LPS/IFN-  or LPS-stimulated cells were collected and assayed
for IL-12 and IFN-  production, respectively, using a commercially avail-
able (BD Biosciences), “two-site sandwich” ELISA kit. Total cellular RNA
was isolated using a commercial TRIzol reagent (Life Technologies).
Northern blot. Mice were killed under anesthesia, and the spleens were
removed and rapidly frozen in liquid nitrogen. Frozen spleens were placed
in TRIzol reagent and were immediately homogenized by mechanical dis-
ruption with a polytron homogenizer (Kinematica), and RNA was further
extracted according to the protocol provided by the manufacturer. Total
spleen RNA (10  g per lane) was analyzed by electrophoresis on a denatur-
ing agarose (1.2%) gel containing 4% formaldehyde, this was followed by
blotting onto a hybridization membrane. The blot was prehybridized and
hybridized (for 16 h each at 65 C) in the same buffer consisting of 1% SDS,
1 M NaCl, and 10% dextran sulfate. Hybridization was performed with an
IRF-8 cDNA fragment (nucleotide positions 179–326) labeled to high spe-
cific activity by random priming with 3,000 Ci/mmol  -[32P]dATP (Perkin-
Elmer). Blots were washed to a final stringency of 0.5  SSC (20  SSC is
3 M sodium chloride and 0.3 M sodium citrate, pH 7.0), 0.5% SDS, for 30
min at 65 C, and exposed to film (BioMax MS; Kodak).
mRNA expression studies by RT-PCR. The level of mRNA expres-
sion of different genes was measured by PCR amplification of cDNA tran-
scripts generated by reverse transcriptase (RT-PCR), as we have described
previously (45). For cDNA synthesis, total spleen RNA (2  g) was reverse
transcribed using 200 U/reaction Moloney MuLV reverse transcriptase (In-
vitrogen) in a 20- l reaction mixture containing 50 mM Tris, pH 8.3, 3
mM MgCl2, 75 mM KCl, 5 ng/ l of randomhexamers, deoxyribonucle-
otides triphosphates (dNTPs; 0.5 mM each), 10 mM DTT, and 36 U of pla-
cental RNase inhibitor (RNAguard; Amersham Biosciences) for 50 min at
37 C. Upon completion of reverse transcriptase reaction, the cDNA mix-
ture was diluted 1:10, of which 2  l was used as a template for PCR ampli-
fication using gene-specific oligonucleotide primer pairs corresponding to
IL-12p40 (5 -gtg aag cac caa att act ccg g-3 ; 5 -gct tca tca tct gca agt tct tgg
g-3 ), IL-12p35 (5 -ggc tac tag aga gac ttc ttc c-3 ; 5 -gtg aag cag gat gca
gag ctt c-3 ), IRF-8 (5 -caa tca gga ggt gga tgc ttc-3 ; 5 -gtc agt cac ttc ttc
aaa atc tg-3 ), and  -actin (5 -aac tgg gac gac atg gag aag-3 ; 5 -acc aga ggc
ata cag gga caa-3 ). Reaction conditions for PCR were those recommended
by the manufacturer of Taq DNA polymerase (Invitrogen), adjusted to 1.4
mM MgCl2, 0.1 mM dNTPs, 1 U Taq DNA polymerase, and 0.3  M oli-
gonucleotide primers in a final volume of 25  l. Parameters for PCR ampli-
fication were 30 s at 94 C, 30 s at 58 –61 C (depending on primmer pair),
30 s at 72 C for 28–30 cycles, followed by a final step at 72 C for 7 min.
The cDNAs were analyzed by electrophoresis on a 1.4% agarose gel con-
taining ethidium bromide and were photographed under UV light.JEM VOL. 201, March 21, 2005 889
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Infection with M. bovis (BCG). M. bovis (BCG, strain Montreal) was
passed in vitro and prepared for in vivo infections as described previously
(46). 2   104 CFU was used to i.v. inoculate mice (2–4 mo old). 21 d after
infection, mice were killed, weighed, and the degree of infection was as-
sessed by determination of spleen CFU, as previously described (47). The in-
dex of BCG infection was defined as the logarithm of the mean number of
viable BCG recovered from spleens. The spleen index (SI) was determined
as the square root of spleen weight ( 100) divided by the body weight.
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